Biobypass

(redirected from Angiogen)

Biobypass

A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow—e.g., in patients with CAD and peripheral vascular disease.

Biobypass®

Cardiology A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow–eg, in Pts with CAD and and peripheral vascular disease. See Angiogenesis.
References in periodicals archive ?
The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as BioBypass angiogen for cardiovascular disease, TNFerade for cancer and AdPEDF for macular degeneration and diabetic retinopathy.
GenVec's lead cardiovascular product candidate is BioBypass angiogen, which is in late-stage randomized Phase II studies in collaboration with Pfizer, Inc.
Microbix is collaborating with Angiogen LLC in the development of the oncology therapy that combines Urokinase with a second small molecule drug.
BIOBYPASS angiogen is now in Phase II clinical trials for the treatment of coronary artery disease and peripheral vascular disease and is being developed in collaboration with Pfizer, Inc.
Community College System, the NC Research Campus houses operations from companies like Anatomics, Angiogen, Carolinas Healthcare System and Red Hat.
Microbix is collaborating with Angiogen LLC in the development of the cancer therapy that combines urokinase with a second drug.
This patent adds an additional layer of proprietary protection for our growing product portfolio, that includes our therapeutic angiogenesis product candidate, BIOBYPASS angiogen, which is now in Phase II clinical studies for the treatment of coronary artery disease.
North Carolina Research Campus Inks Deal with Angiogen, LLC
Microbix and Angiogen LLC are collaborating in the development of a cancer therapy that combines urokinase with a second drug.
But Platten had his own funding through the privately held Australian company Angiogen Pharmaceuticals, so Steinman was game to see where the idea could go.
TSX: MBX) is partnering with Angiogen LLC of Evanston, Ill.